【DPHARMA 7148 交流专区】（前名 CCMDBIO）

北乔峰

CCM DUOPHARMA BIOTECH (7148)
哇! 34仙的超高股息! 消息一出, DBIOTECH 马上起死回生. 加上年初时的 14仙股息, 目前为止就大方派了 48仙! 奇怪, DBIOTECH 真的这么赚钱吗?

不错, 这是一只现金牛, 没有债务, 盈利稳定. 可是, 自从被 CCM 掌管后, 业绩也没有再进步了.

股本 : 139 mil
股息 : RM 0.48 x 139 mil = RM 66.72 mil

2007 全年盈利预计也不过 RM 30mil. 哪来的钱啊?

CCM 还说是业绩好, 所以派高息. 你信吗?

还不是从现金保留的 RM 55mil 挖出来. 当然, 公司没有任何发展大计, 把钱拿出来分, 好过来年提高董事薪金.

问题是, 然后呢? 前景呢?


挤了这么大桶奶, 还不是掉入 CCM 的口袋…

股息除权后, 它的命运会如何呢? 明年还可能这么慷慨吗?


[ 本帖最后由 Mr.Business 于 3-3-2008 09:17 AM 编辑 ]

publicpang

公司ID是什么....好象没听过这间公司.....

scsiang82

公司ID是CCMDBIO

publicpang

7148 CCMDBIO, CCM DUOPHARMA BIOTECH BHD

Special Interim Dividend 68% 26 Nov 2007, 17:26 Entitlement Type OTHERS Entitlement Amt (RM/%) 68% Entitlement Date & Time 7 Dec 2007, 16:00 Year/Period Ending/Ended on 31 Dec 2007 Ex-Date 5 Dec 2007 Payment Date 24 Dec 2007 Stock Par Value 0.50 Entitlement Description Special Interim Dividend of 68% (34 sen) per share less 27% income tax Eligibility for Entitlement • Securities transferred into the Depositor's Securities Account before 7 Dec 2007, 16:00 in respect of transfers. • Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange.

pc255

dividend 对小股东好

reporting notes:
"This is in line with the increase in profit after tax and also changes in tax legislation from imputation system to single tier system"
probably try to frank out of the sec108 accumulated tax.

"这是一只现金牛, 没有债务, 盈利稳定. 可是, 自从被 CCM 掌管后, 业绩也没有再进步了."
like uchi, this have change from a growth stock to a div yield stock

08 budget 对这样的股票以后可能不大好

Mr.Business

原帖由 m~v 于 6-7-2007 02:44 AM 发表
买进: CCM DUOPHARMA BIOTECH (7148)
理由: 1) 业绩良好
         2) 没有债务 d/e= 0
         3) 跟政府２年的契约
         4) 高股息
         5) 母公司,ccm.
         6)抗跌股

傻人最有傻福

General Announcement

Reference No CD-090223-61609

Submitting Merchant Bank	:	-
Company Name	:	CCM DUOPHARMA BIOTECH BERHAD
Stock Name	:	CCMDBIO
Date Announced	:	24/02/2009

Type	:	Announcement
Subject	:	[table=98%]
CCM Duopharma Biotech Berhad - Proposed Final Tax Exempt Dividend

[/td][/tr][tr][td=3,1]
[

sunday365

CCM Duopharma Bhd’s (CCMD) contracts to supply drugs to the Health Ministry are worth over RM30mil per annum.

The anti-viral drug, Tamiflu, is now sold at all 1,800 pharmacies nationwide.
Some 6,000 pharmacists have been strictly told to dispense the drug to only those with a doctor's prescription.

It comes in capsule form of 30mg, 45mg or 75mg.

Three companies -- Roche (M) Sdn Bhd, Ranbaxy (M) Sdn Bhd and CCM Duopharma Biotech Berhad -- are involved in the supply of Tamiflu.

chgchksg128

请放链接（link）
找不到相关的新闻。

sunday365

Currency in	As of:	2-Jan	2-Jan	2-Jan	2-Jan
Millions of Malaysian Ringgits		2006	2007	2008	2009
Revenues		94.3	105.1	115.6	122.9
TOTAL REVENUES		94.3	105.1	115.6	122.9
Cost of Goods Sold		45.7	48.2	52.2	62.2
GROSS PROFIT		48.6	57	63.4	60.6
Selling General & Admin Expenses, Total		15.7	18.8	21.1	23.9
Other Operating Expenses		0.6	1.6	1.3	1.8
OTHER OPERATING EXPENSES, TOTAL		16.3	20.4	22.4	25.7
OPERATING INCOME		32.4	36.6	40.9	34.9
Interest and Investment Income		0.7	1.5	1.6	0.4
NET INTEREST EXPENSE		0.7	1.5	1.6	0.4
Income (Loss) on Equity Investments		0.3	--	--	--
EBT, EXCLUDING UNUSUAL ITEMS		33.4	38	42.5	35.3
Gain (Loss) on Sale of Assets		--	0	0	0.1
EBT, INCLUDING UNUSUAL ITEMS		33.4	38.1	42.5	35.3
Income Tax Expense		9.9	9.1	10.5	7.9
Earnings from Continuing Operations		23.5	29	32	27.4
NET INCOME		23.5	29	32	27.4

sunday365

Currency in	As of:	2-Jan	2-Jan	2-Jan	2-Jan
Millions of Malaysian Ringgits		2006	2007	2008	2009
Assets
Cash and Equivalents		52.4	54.4	9.4	18.4
Short-Term Investments		0.1	0.1	0.1	0
TOTAL CASH AND SHORT TERM INVESTMENTS		52.5	54.4	9.5	18.4
Accounts Receivable		25.1	26.5	33.3	32.9
Other Receivables		0	1.6	0.4	2
TOTAL RECEIVABLES		25.1	28.1	33.8	34.9
Inventory		15.8	20.8	24.5	33.6
Other Current Assets		--	--	--	8.1
TOTAL CURRENT ASSETS		93.4	103.3	67.8	95
Gross Property Plant and Equipment		79.1	75.7	84	90.3
Accumulated Depreciation		-22.3	-26.1	-30.5	-34.9
NET PROPERTY PLANT AND EQUIPMENT		56.8	49.7	53.5	55.4
Long-Term Investments		1.3	--	--	--
Other Long-Term Assets		--	6.1	6.1	--
TOTAL ASSETS		151.6	159	127.3	150.4

sunday365

LIABILITIES & EQUITY
Accounts Payable		3.3	4.2	4	6
Accrued Expenses		2.1	5.2	4.8	6.5
Current Income Taxes Payable		1.3	0	0.2	--
Other Current Liabilities, Total		1.3	1.3	0.3	3.6
TOTAL CURRENT LIABILITIES		8	10.7	9.4	16
Deferred Tax Liability Non-Current		2.8	2.8	3.7	3.8
Other Non-Current Liabilities		2.9	--	--	--
TOTAL LIABILITIES		13.7	13.6	13.1	19.8
Common Stock		69.7	69.7	69.7	69.7
Additional Paid in Capital		13.5	13.6	13.7	13.7
Retained Earnings		54.6	63.2	31.9	48.2
Treasury Stock		-1.6	-1.6	-1.6	-1.6
Comprehensive Income and Other		1.7	0.4	0.4	0.4
TOTAL COMMON EQUITY		137.9	145.4	114.2	130.6
TOTAL EQUITY		137.9	145.4	114.2	130.6
TOTAL LIABILITIES AND EQUITY		151.6	159	127.3	150.4

sunday365

Currency in	As of:	2-Jan	2-Jan	2-Jan	2-Jan
Millions of Malaysian Ringgits		2006	2007	2008	2009
NET INCOME		23.5	29	32	27.4
Depreciation & Amortization		4.2	4.7	4.6	4.8
Amortization of Goodwill and Intangible Assets		-0.5	--	--	--
DEPRECIATION & AMORTIZATION, TOTAL		3.7	4.7	4.6	4.8
(Gain) Loss from Sale of Asset		0	0	0	-0.1
(Gain) Loss on Sale of Investment		--	0	--	--
Asset Writedown & Restructuring Costs		--	--	--	-1.9
Other Operating Activities		2.9	-4.1	0.8	-1.5
(Income) Loss on Equity Investments		-0.3	--	--	--
Change in Accounts Receivable		-2.7	-1.6	-7.1	0
Change in Inventories		-2.1	-4.9	-3.8	-9
Change in Accounts Payable		-1.9	4	-1.5	6.8
CASH FROM OPERATIONS		23.1	27	25.1	26.5

sunday365

Capital Expenditure		-7.1	-4.6	-8.5	-6.9
Sale of Property, Plant, and Equipment		0	1	0.1	0.1
Investments in Marketable & Equity Securities		--	1.3	--	--
CASH FROM INVESTING		-6.4	-0.8	-6.8	-6.4
Issuance of Common Stock		17.1	0.2	0.1	0
Repurchase of Common Stock		-1.6	--	--	--
Common Dividends Paid		-5.8	-24.5	-28.9	-11.1
TOTAL DIVIDEND PAID		-5.8	-24.5	-28.9	-11.1
Special Dividend Paid		--	--	-34.5	--
CASH FROM FINANCING		9.7	-24.3	-63.3	-11.1
NET CHANGE IN CASH		26.4	2	-45	9

某某闲人

原帖由 chgchksg128 于 15-8-2009 02:24 PM 发表
请放链接（link）
找不到相关的新闻。

http://www.nst.com.my/Current_News/NST/articles/8antt/Article/index_html

cct2049

27-11-2007的新闻

青天白月

马来西亚防疫不力，看来大流行是避不了的了，大家要改善日常作息，早睡早起,备带口罩，可服用一些可以提升免疫力的保健品比如 Bio-esther C or Redoxon C effervesant or Bee Propolis or Allisure Standardised Garlic Extract.

当然也可先订一盒Tamiflu,以备不时之需。。。怕会货源不足。。

ShynanGoh

CCMDBIO ..."过热"了 ??? .... ....
小心留意政府有没更新政策... ....

[ 本帖最后由 ShynanGoh 于 16-8-2009 06:39 PM 编辑 ]

sunday365

Local drug sector to reach RM3.9b
By ELAINE ANG


The industry is expected to grow 10% this year

PETALING JAYA: The local pharmaceutical industry is expected to grow some 10% to US$1.1bil (RM3.9bil) this year versus 2008, fuelled by increased demand for medication due to the Influenza A(H1N1) pandemic, according to the Malaysian Organisation of Pharmaceutical Industries (MOPI).

MOPI president Jimmy Piong said the pharmaceutical industry was recession-proof and was less affected by the economic downturn than other industries.

“Sales of prescription medicine have not been affected as people are still getting sick.

“However, products that consumers buy over the counter such as vitamins and non-prescriptive drugs are growing at a slower rate as they buy less to save cost. Sales of immune boosters have grown because of the influenza (pandemic),” Piong told StarBiz.


Local generic pharmaceutical manufacturers, however, are forecast to have about 15% growth this year and next as more in the medical fraternity and consumers switch to generics to cut costs.

For example, prices of branded/patented drugs are said to have jumped 12% to 15% last year while that of generic medicine increased 3% to 5% due to the rise in raw material costs.

Generic pharmaceuticals currently comprise some 35% or US$350mil (RM1.23bil) of the domestic industry.

In addition to the expected growth in local consumption, Piong also foresees export-driven growth boosting the generic pharmaceutical business.

“There has been a trend of local players expanding overseas recently. Currently, local generic manufacturers such as CCM Duopharma Biotech Bhd and Pharmaniaga Bhd export about RM200mil worth of products annually.

“We expect to see exports grow 15% to 30% in three years,” he said.

Piong said generally, it took about three years to obtain from a target country the marketing approval for a pharmaceutical product.

The catalyst for the expected growth in exports is that Malaysia’s standards and technology have fulfilled Good Manufacturing Practice according to the European Pharmaceutical Inspection Convention Code as the country is a member of its Pharmaceutical Inspection Cooperation Scheme.

At present, generic players export to 43 countries with a focus on the Asean region.

To MOPI first vice-president Leonard Ariff Shatar, contract manufacturing is another growth driver.

“The potential of contract manufacturing is high especially since Malaysia’s standards are now recognised worldwide. Many products are also expected to come off-patent in 2012 and 2013,” he said.

Nevertheless, generic manufacturers also face a host of challenges including rising competition and tighter regulation.

Piong noted that there was an industry shift by multinational pharmaceutical companies towards the manufacture of generic products, thus increasing competition for local players.

Regulatory standards are also anticipated to become more stringent.

Leonard stressed that generic drugs worked as well as patented ones and had to undergo various tests and standards before going to market.

Currently, it takes about 18 months before a new drug can be registered in the country.

Moreover, generic drugs go through clinical testing for bio-equivalency (BE) to ensure that they have the same potency, efficacy, effects and side effects as the original drugs.

Leonard pointed out that it took a minimum RM500,000 to obtain approval to market a generic product and about three to four years before it could go to market.

Pharmaniaga managing director Mohamad Abdullah concurs.

“We conduct BE tests to ensure the safety and efficacy of our products and need to get the necessary approvals from the authorities before they go to market.

The group has a 15-year concession to supply and distribute pharmaceutical and medical products to hospitals and medical institutions under the Health Ministry.

sunday365

CCMD Q2 Pre-tax Profit At RM10.978 Million


KUALA LUMPUR, Aug 26 (Bernama) -- CCM Duopharma Biotech Bhd (CCMD)'s pre-tax profit for the second quarter ended June 30, 2009 increased to RM10.968 million compared with RM10.784 million in the previous corresponding period.

Its revenue rose to RM34.062 million from RM33.505 million.

For the six months period, its pre-tax profit came down marginally to RM20.337 million from RM20.630 million in the previous half-year financial period.

Revenue however rose to RM61.728 million from RM60.977 million.

CCMD has recommended an interim tax exempt dividend of 12 per cent (six sen) per share (2008: 16 per cent (eight sen)).

The proposed dividend is however lower than last year's figure mainly due to CCMD's capex requirement in constructing new warehousing facilities and also staff amenities, it said in a statement Wednesday.

The book closure date in respect of the interim tax exempt dividend is on October 5 and the dividend will be paid on October 23.

Following the growing number of influenza A (H1N1) cases and deaths in Malaysia, CCMD launched Omiflu, an anti-viral drug to treat infections due to the influenza virus.

The Omiflu capsule of 75mg contains oseltamivir phosphate 98.5mg which slows down the rate at which influenza virus infects cells in the body and reduces the symptoms to give the body a better chance of fighting the virus, it said.

The company said it was also on track to establish the first inert vaccines fill and finish facility in the ASEAN region by the fourth quarter of this year.

The RM7 million facility is suitable for the vialling of CCMD's bulk vaccines in the pipeline and is capable of compounding, filling, freeze drying, capping, inspecting, labeling and packing inert vaccines, it said.

CCMD is a subsidiary of CCM Bhd which is listed on Bursa Malaysia and a key player in the fertilizers, chemicals and pharmaceuticals industries.

-- BERNAMA